|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To enhance the efficacy of rMETase, we have constructed the pLGFP-METSN retrovirus encoding the P. putida methioninase (MET) gene fused with the green fluorescent protein (GFP) gene. pLGFP-METSN or control vector pLGFPSN was introduced into the human lung cancer cell line H460.
|
10770644 |
2000 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
These regions are frequently (30-80%) deleted in human lung cancer and contain tumor suppressor genes or proto-oncogenes such as MET, CDKN2A/p16/MTS1, CDKN2B/p15/MTS2, FHIT, and RB1 or yet to be identified genes.
|
10918387 |
2000 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We first showed that human myofibroblasts derived from primary lung cancer expressed c-MET mRNA and protein by reverse transcription-polymerase chain reaction and Western blot analysis.
|
11290563 |
2001 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The c-Met protein was downregulated by 50-60% in two lung cancer cell lines that were transiently transfected with the c-Met antisense versus U6 control.
|
14737093 |
2004 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of genomic DNA of 126 lung adenocarcinoma patients for the Met juxtamembrane domain revealed the same Arg/Cys variation at the mouse homologous position in one patient; two other patients carried additional variants in the same domain, suggesting a potential role for rare MET juxtamembrane variants in human lung cancer.
|
15592501 |
2005 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To assess the functional role for Met in NSCLC, we evaluated a panel of nine lung cancer cell lines for Met gene amplification, Met expression, Met pathway activation, and the sensitivity of the cell lines to short hairpin RNA (shRNA)-mediated Met knockdown.
|
17332337 |
2007 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib.
|
17463250 |
2007 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies show that the presence of c-Met gene amplification is predictive for selective c-Met TK inhibitors in gastric cancer and lung cancer.
|
18395971 |
2008 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
This paper will review the structure, function, mechanisms of tumorigenesis, and potential for therapeutic inhibition of the MET receptor in lung cancer and mesothelioma.
|
18672314 |
2009 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET would be an important therapeutic antitumor target to be inhibited, and in lung cancer, MET may represent a cancer early progenitor cell marker.
|
18709663 |
2008 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Exogenous miR-1 significantly reduced expression of oncogenic targets, such as MET, a receptor tyrosine kinase, and Pim-1, a Ser/Thr kinase, frequently up-regulated in lung cancer.
|
18818206 |
2008 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The detection of gene activation in multiple cohorts of samples strongly supports the presence of key genes involved in lung cancer that are distinct from the EGFR and MET loci on chromosome 7.
|
19088816 |
2008 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET gene copy number was determined by real-time quantitative polymerase chain reaction in 187 of the patients with lung cancer and the MET gene splice mutation deleting the juxtamembrane domain was examined by direct sequencing in 262.
|
19096300 |
2009 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.
|
19117057 |
2009 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical resistance to epidermal growth factor receptor (EGFR) inhibition in lung cancer has been linked to the emergence of the EGFR T790M resistance mutation or amplification of MET.
|
19351834 |
2009 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Research on signaling pathways dysregulated in lung cancer is ongoing, including investigation of the hepatocyte growth factor receptor (HGFR) or c-Met.
|
19393836 |
2009 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study examines the ethnic differences in the type and frequency of MET proto-oncogene (MET) mutation in lung cancer and correlated them with other frequently mutated genes such as epidermal growth factor receptor (EGFR), KRAS2, and TP53.
|
19723643 |
2009 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The hepatocyte growth factor receptor, c-Met is overexpressed in a variety of cancers including lung cancer and Sp proteins mediate the regulation of c-Met.
|
19851711 |
2011 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
CL-387,785 sensitivity and signal transduction in H1975 cells were examined in the presence or absence of HGF or HGF-producing fibroblasts with or without HGF-MET inhibitors.
|
20008840 |
2010 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
|
20126411 |
2010 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical implications of MET gene copy number in lung cancer.
|
20146583 |
2010 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) and MET are molecular targets for lung cancer treatment.
|
20934974 |
2010 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
CTD_human |
Epidermal growth factor receptor (EGFR) and MET are molecular targets for lung cancer treatment.
|
20934974 |
2010 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
|
21062933 |
2010 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that EMT developed in a lung cancer patient who had an acquired resistance to erlotinib while there were no known resistant mechanisms such as T790M and MET amplification.
|
21168239 |
2011 |